Singapore’s S*BIO Licenses Leukemia Agent SB1317 To U.S.-Based Tragara
This article was originally published in The Pink Sheet Daily
Executive Summary
The multi-kinase inhibitor might have stalled after S*BIO focused on funding its first two candidates in the clinic, CEO says. The company is still involved in preclinical development.